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The presence of cardiovascular disease (CVD) in Type 1 diabetes largely impairs life expectancy. Hyperglycemia
leading to an increase in oxidative stress is considered to be the key pathophysiological factor of both micro- and
macrovascular complications. In Type 1 diabetes, the presence of coronary calcifications is also related to coronary
artery disease. Cardiac autonomic neuropathy, which significantly impairs myocardial function and blood flow, also
enhances cardiac abnormalities. Also hypoglycemic episodes are considered to adversely influence cardiac
performance. Intensive insulin therapy has been demonstrated to reduce the occurrence and progression of both
micro- and macrovascular complications. This has been evidenced by the Diabetes Control and Complications Trial
(DCCT) / Epidemiology of Diabetes Interventions and Complications (EDIC) study. The concept of a metabolic
memory emerged based on the results of the study, which established that intensified insulin therapy is the
standard of treatment of Type 1 diabetes. Future therapies may also include glucagon-like peptide (GLP)-based
treatment therapies. Pilot studies with GLP-1-analogues have been shown to reduce insulin requirements.
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Over the past 40 years, a reduction in the mortality due to
cardiovascular (CV) disease and coronary heart disease
(CHD) by about 70% both in diabetic and non-diabetic pa-
tients has been observed [1]. The cause is presumed to be a
substantial progress in CV risk factor management and
interventional cardiology [1]. Furthermore, in patients with
type 1 diabetes, a decrease in mortality and a remarkable
improvement in life expectancy occurred during the past
decades [2,3]. The comparison of two subcohorts of the
Pittsburgh Epidemiology of Diabetes Complications study
based on the period of diabetes diagnosis (1950–1964
vs. 1965–1980) found an increase in life expectancy by
approximately 14 years [3]. Nevertheless, the overall risk of
CVD for people with type 1 diabetes compared to people
without diabetes is increased two- to threefold in men, and
three- to fivefold in women. A significant increase in CVD
mortality related to increasing HbA1c levels has been re-
ported in type 1 diabetes [4].
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lation between type 1 diabetes and CVD. In addition, the* Correspondence: Oliver.Schnell@lrz.uni-muenchen.de
1Forschergruppe Diabetes e.V., Helmholtz Center Munich, Ingolstaedter
Landstrasse 1, 85764 Munich-Neuherberg, Germany
Full list of author information is available at the end of the article
© 2013 Schnell et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the ormanagement of risk factors, both with view on diagnostic
and therapeutic approaches, is addressed.Epidemiology
In the EURODIAB IDDM Complications Study, including
more than 3.200 patients with type 1 diabetes from 16
European countries, the prevalence of CVD was reported
to be 9% in men and 10% in women, respectively [5].
Related to an increase in duration of diabetes and age, an
increase from 6% in the age group of 15–29 years to 25%
in the age group of 45–59 years, has been observed [5].
In type 1 diabetes as compared to type 2 diabetes,
the relationship of hyperglycemia with microangiopathy
as well as macroangiopathy seems to be more significant
[6,7]. According to the results of a large Finnish data-
base, CVD mortality in patients with type 1 diabetes
aged from 45–64 years at baseline increases by about
50% with every 1% increase of glycated haemoglobin
(HbA1c) [6].
In a population-based cohort of 879 individuals with
type 1 diabetes from Wisconsin, hyperglycemia was as-
sociated with all-cause and cardiovascular mortality [8].
At baseline examination (1980–1982), patients were free
of cardiovascular disease and end-stage renal disease. The
patients were followed up until December 2001. The multi-
variable relative risks comparing the highest quartile ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(95% CI: 1.54, 3.82; p-trend = 0.0006) for all-cause mortality
and 3.28 (95% CI: 1.77, 6.08; p-trend < 0.0001) for car-
diovascular mortality [8]. This association was present
among both sexes, and independent of duration of dia-
betes, smoking, hypertension, and proteinuria. The re-
lation persisted in subgroup analyses by categories of
diabetes duration, smoking, body mass index, proteinuria,
and retinopathy [8].
In a Japanese study, which included type 1 diabetes, who
were diagnosed at an age of <18 years between 1965 and
1979, CVD was identified as the leading cause of death
in diabetes of more than 20 years of duration [9].
Recently, the long-term clinical outcomes and survival
in patients with both young-onset type 2 and type 1 dia-
betes with a similar age of diagnosis were evaluated
[10]. As compared with type 1, type 2 demonstrated to
present to be associated with a more lethal phenotype
and a higher mortality. Also diabetic complications were
detected more frequently [10].
Pathophysiology / Etiology
Long-term hyperglycemia, both in type 1 and type 2
diabetes, leads to microvascular and macrovascular
complications [11]. Microvascular damage affects par-
ticularly the retina, kidneys, both the autonomic and
peripheral nervous system, while the heart, brain, lower
limbs, are affected by both micro- and macrovascular
disorders [11].
Oxidative stress
Hyperglycemia-induced overproduction of superoxide by
the mitochondrial electron-transport chain is supposed to
be the key element in the activation of all other pathways
involved in the pathogenesis of diabetic complications
(Figure 1) [12,13]. These include an increase in polyol path-
way flux and advanced glycation end product formation,
an activation of protein kinase C, and an increase in
hexosamine pathway flux. Superoxide overproduction
is accompanied by increased nitric oxide generation,
due to an endothelial nitric oxide synthase (NOS) and
inducible NOS uncoupled state. Thus, the formation of the
strong oxidant peroxynitrite is favoured, which in turn is
damaging deoxyribonucleic acid (DNA) [12,13].
Due to this DNA damage, a rapid activation of poly
(adenosine diphosphate [ADP]-ribose) polymerase occurs,
in turn depleting the intracellular concentration of its
substrate nicotinamide adenine dinucleotide (NAD+), and
slowing the rate of glycolysis, electron transport, and
adenosintriphosphate (ATP) formation. In addition, the
ADP-ribosylation of the glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) is stimulated. These processes
result in acute endothelial dysfunction, which is contrib-
uting to the genesis of diabetic complications [12,13].Inflammation
Also an increase in inflammatory cytokines is sup-
posed to contribute to plaque instability in patients
with diabetes [14]. Several inflammatory markers including
C-reactive protein, interleukin (IL)-6, IL-8, tumor ne-
crosis factor (TNF)-α, and endothelin-1 are increased
during hypoglycemia. The accumulation of inflamma-
tory cytokines is assumed to cause endothelial injury
and abnormalities in coagulation, resulting in increased
risk for CV events [14].
Hypercoagulability
The coagulation system is altered due to changes in
clotting factor levels and/or activity. Plasma levels of
procoagulant factors are increased while fibrinolytic
capacity is decreased [15]. Hyperinsulinemia results in
increased hepatic synthesis of prothrombotic factors
such as fibrinogen and plasminogen activator inhibitor
(PAI)-1, thereby creating a thrombotic milieu. Furthermore,
diabetes causes quantitative modifications in clotting fac-
tors, including glycation and oxidation which also increase
thrombosis risk [15].
Autonomic neuropathy
Cardiac autonomic neuropathy (CAN) detected by stand-
ard tests is a common complication of type 1 diabetes.
CAN prevalence is around 20% and increases with age
and diabetes duration with an about 2% annual increase
[16]. Poor glycemic control is a strong risk factor for CAN
as supported by the EURODIAB study [17]. In the DCCT
study intensive insulin treatment reduced the incidence
of CAN by 53% compared to conventional therapy [18].
In the EDIC study, at the 13th-14th year after DCCT
closeout, the prevalence and incidence of CAN remained
significantly lower in the former intensive than in the
former conventional group [19].
Several studies showed the predictive value of CAN on
mortality [16] and that CAN is an independent predictor
of mortality. CAN was reported to be a predictor of CV
morbidity and mortality in type 1 diabetes [20]. Various
CV disorders associated with CAN and resulting from
vagal impairment and sympathetic predominance were
shown mostly in type 2 diabetes and may account for the
poor prognosis related to CAN [16]. Such disorders have
been far less studied in patients with type 1 diabetes. In a
study on patients with type 1 and type 2 diabetes, the
prevalence of hypertension was shown to increase with
CAN severity (from 3.6% in the patients without CAN to
36.4% in those with severe CAN), and CAN was an inde-
pendent risk factor for hypertension [21]. This association
suggests that vagosympathetic imbalance with a relative
sympathetic overdrive may be involved in hypertension.
In the Pittsburgh EDC study, CAN was associated with
increased arterial stiffness 18 years later [22]. There is
Figure 1 Pathogenesis of diabetic complications: Hyperglycemia-induced overproduction of superoxide by the mitochondrial
electron-transport chain is supposed to be the key element. By activation of different pathways, the formation of the strong oxidant
peroxynitrite is favoured, which in turn is damaging DNA. Through several intermediate steps, acute endothelial dysfunction, contributing to the
genesis of diabetic complications, is triggered [13].
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type 1 or type 2 diabetes, that QT interval prolongation
is an independent predictor of mortality, for all-cause
and for cardiovascular deaths [16].
The balance of the activity of the autonomic nervous
system is considered to play a key role for the performance
of the diabetic heart [23]. Advanced single-photon emission
computed tomography (SPECT) and positron emission
tomography (PET) allow to directly and sensitively assess
cardiac sympathetic innervation [24-29], coronary blood
flow [30,31] and myocardial metabolism [32,33]. In long-
term type 1 diabetes, myocardial blood flow response to
sympathetic stimulation is significantly impaired.
Scintigraphically, cardiac sympathetic dysinnervation was
identified in 77% of newly diagnosed metabolically stabi-
lized type 1 diabetic patients [27]. The pattern of cardiac
sympathetic dysinnervation of newly diagnosed type 1
diabetic patients is heterogeneous with a predominant
affection of the posterior myocardial region [25,27]. More
recent publications, however, emphasize that neither
impairment of metabolic control nor the presence of CV
denervation may be a prerequisite for the development of
impaired vasodilatory reserve. Diastolic dysfunction occur-
ring early in the course of type 1 diabetes has been reported
to be associated with abnormal cardiac sympathetic func-
tion as assessed by cardiac sympathetic imaging [34,35].
Neuronal abnormalities are reported to progress with
duration of diabetes [36]. In parallel, defects of cardiacsympathetic innervation are more enhanced in long-term
than in newly diagnosed type 1 diabetic patients [25,27].
In patients with a long diabetes history, heterogeneity
of cardiac sympathetic dysinnervation, characterized by a
more advanced affection of the posterior myocardium in
comparison to the anterior, lateral and septal myocardium
has been observed [25]. In studies on small groups of pa-
tients with type 1 diabetes, frequent sympathetic dysinner-
vation and a predominance in the posterior myocardial
region [37], and proximal sympathetic hyperinnervation
of the heart [38] has been observed with PET.
Immunological factors against sympathetic ganglia have
been reported to be associated with cardiac sympathetic
dysfunction [39-45]. Autoantibodies against sympathetic
ganglia have been found in 20-35% of type 1 diabetic
patients [39,41,42]. The presence of autoantibodies against
sympathetic ganglia has been shown to be associated with
scintigraphically assessed cardiac sympathetic dysfunction
[39,41] and electrocardiogram (ECG)-based abnormalities
of heart rate variation [41]. Autoantibodies against sympa-
thetic ganglia seem to be rather specific for cardioneuro-
pathy of type 1 diabetic patients [41].
Hypoglycemia
Additional hemodynamic changes have been reported to be
associated with hypoglycemia [46]. An increase in heart rate
and peripheral systolic blood pressure as well as a reduction
in central blood pressure and peripheral arterial resistance
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Furthermore, an increase in myocardial contractility, stroke
volume, and cardiac output has been observed [47]. In
healthy people, arteries have been reported to become
more elastic during hypoglycemia with a decline in wall
stiffness [46]. In people with a longer history of type 1
diabetes, however, due to an enhanced arterial wall stiffness,
hypoglycemia is followed by a less pronounced fall in
central arterial pressure [46,48]. As a consequence, tem-
porarily a markedly increase in the workload of the heart
has to be assumed [46].
In the ECG, hypoglycemia has been found to elicit ST
wave changes with lengthening of the QT interval [49]
and cardiac repolarization [50]. Thereby, the risk for
arrhythmia is assumed to be increased [46]. Related to
hypoglycemia, various abnormal heart rhythms, including
ventricular tachycardia and atrial fibrillation, have been
observed. In conclusion, hypoglycemia has been found to
potentially cause abnormal electrical activity in the heart
and is assumed to can provoke sudden death [46].
An association between hypoglycemia and sudden death
has been deteced by different investigators [51-56]. In line
with the hypothesis an autopsy study demonstrated, that
sudden unexpected deaths were four times more frequent
in type 1 diabetic patients than in nondiabetic people [56].
CV risk
Risk factors for microvascular complications
The risk of microvascular complications is influenced by
several factors, such as puberty, blood pressure, dyslip-
idemia, gender, diabetes duration, smoking and lifestyle
[57-59]. Poor metabolic control was identified as an
important factor contributing to microvascular com-
plications [60,61]. In addition, familial risk factors re-
lated to all microvascular complications of type 1
diabetes have been reported [62]. A study performed in
type 1 diabetic patients (onset age < 30 years) among
6,707 families revealed a significantly increased risk of
retinopathy (odds ratio 9.9; CI 5.6–17.7, P < 0.001), ne-
phropathy (6.2; CI 2.9–13.2, P < 0.001) and neuropathy
(2.2; CI 1.0–5.2; P < 0.05) in type 1 diabetic siblings of
patients diagnosed with those complications [62].
In an analysis of 572 type 1 diabetic participants of the
Pittsburgh EDC Study (mean follow-up: 15 years), baseline
HbA1c was an independent risk factor for fatal CAD, along
with duration of diabetes and albuminuria [63]. Baseline
lower insulin dose, however, was strongly predictive for
non-fatal CAD, as was lower renal function, higher diastolic
blood pressure, and lipids [63].
In patients with diabetes onset at age 5–14 years, a
higher risk for complications (retinopathy, nephropathy,
and neuropathy) has been found as compared to patients
diagnosed either at a very young age or after puberty
[62]. In adolescents with type 1 diabetes, an elevated bloodpressure or BMI [64-66], dyslipidemia and smoking [67-69]
are associated with an elevated risk of incipient nephropa-
thy, early retinopathy and peripheral neuropathy.
With the onset of diabetic nephropathy, a dramatic
increase in the risk for CAD has to be assumed. After 20
years with diabetes, up to 29% of patients with childhood-
onset of type 1 diabetes and nephropathy will have CAD
compared to only 2–3% in similar patients without ne-
phropathy [70]. In addition to traditional cardiovascular
disease risk factors, elevated mean HbA1c and macroal-
buminuria are significantly associated with alterations
in left ventricular structure and function evaluated by
cardiac magnetic resonance imaging (MRI) [71].
In observational studies the relationship between blood
pressure and the progression of chronic kidney disease
(CKD) and incident end-stage renal disease (ESRD) is direct
and progressive in diabetes [72]. However, most of the evi-
dence is in type 2 diabetes, high blood pressure is a common
feature also of type 1 diabetes and an increase in blood
pressure in type 1 diabetes increases the risk of nephropa-
thy [73,74]. Masked hypertension is not infrequent [72].
In people with type 1 diabetes an increase in systolic blood
pressure, particularly at night, precedes the development of
microalbiminuria [75]. It has been argued that, unlike in
type 2 diabetes, in people with type 1 diabetes hypertension
develops often after the establishment of microalbuminuria.
Hence, monitoring blood pressure throughout the 24 hours
in type 1 diabetes may be a useful diagnostic procedure.
In the DCCT/EDIC study, during a 15.8-year median
follow-up, 630 of 1441 participants developed hypertension
[76]. Intensive therapy during the DCCT reduced the risk
of incident hypertension by 24% during EDIC study follow-
up. A higher HbA1c level, measured at baseline or during
follow-up, was associated with increased risk for incident
hypertension. Older age, male sex, family history of hyper-
tension, greater baseline body mass index, weight gain, and
greater albumin excretion rate were independently associ-
ated with increased risk of hypertension. These data show
that hyperglycemia is a risk factor for incident hypertension
in type 1 diabetes and that intensive insulin therapy reduces
the long-term risk of developing hypertension.
In a recently published Brazilian study on approximately
1,300 patients with type 1 diabetes, however, body size and
blood pressure were not correlated to lipid levels and gly-
cemic control [77]. Correlation of serum lipids with HbA1c
was shown to be heterogeneous across the spectrum of gly-
cemic control. Several pathophysiological factors were sug-
gested based on the HbA1c-level. These results, therefore,
do not support a unified explanation for cardiovascular risk
in type 1 diabetes [77].
Cardiovascular risk markers
As demonstrated in 144 participants of the Pittsburgh
EDC Study, pulse wave analysis (PWA) may contribute
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betes [78]. Arterial stiffness index, augmentation index,
augmentation pressure, subendocardial viability ratio
(serving as an estimate of myocardial perfusion), electron
beam computed tomography-measured coronary artery
calcification (CAC) and ankle-brachial index (ABI) were
determined. In the analysis of cross-sectional associa-
tions, greater augmentation pressure was independently
associated with prevalent CAD and estimated myocardial
perfusion with low ABI (<0.90) [78].
In the DCCT/EDIC study the stiffness/distensibility of
the ascending thoracic aorta was measured with magnetic
resonance imaging in 879 patients [79]. After adjusting for
gender and cohort, aortic distensibility was lower with in-
creasing age, mean systolic blood pressure, LDL cholesterol,
and HbA1c measured over an average of 22 years. Patients
with macroalbuminuria had 25% lower aortic distensibility
compared with those without, and lower distensibility
also was associated with greater ratio of left ventricular
mass to volume. This data stand in favour of strong adverse
effects of hypertension, chronic hyperglycemia and macro-
albuminuria on aortic stiffness in type 1 diabetes.
After 15 years additional follow-up in EDIC, left ventricu-
lar indices were measured by cardiac magnetic resonance
imaging in 1017 of the 1371 members of the DCCT cohort
[80]. Mean DCCT/EDIC HbA1c over time was associated
with end diastolic volume, stroke volume, cardiac output,
left ventricular mass, LV mass/EDV, and aortic distensibil-
ity. These associations persisted after adjustment for CVD
risk factors. Thus, cardiac function and remodeling in the
EDIC cohort was associated with prior glycemic exposure
(glycemic memory).
As part of the EDIC study, 1229 patients with type 1
diabetes underwent ultrasonography of the internal
and common carotid arteries in 1994–1996 and again
in 1998–2000 [81]. At year 1 of the EDIC study, the carotid
intima-media thickness (IMT) was similar to that in an
age- and sex-matched nondiabetic population. After six
years, the IMT was significantly greater in the diabetic
patients than in the controls. The mean IMT progres-
sion was significantly less in the group that had received
intensive therapy during the DCCT than in the group
that had received conventional therapy after adjustment
for other risk factors. IMT progression was associated with
age, and the EDIC base-line systolic blood pressure, smok-
ing, the LDL/HDL ratio, and urinary albumin excretion rate
and with the mean HbA1c value during the mean duration
of the DCCT. Thus, intensive therapy during the DCCT
resulted in decreased progression of IMT six years after
the end of the trial, which again stands in favour of the
effect of glycemic memory.
As found by the 10-year follow-up examination of the
Pittsburgh Epidemiology of Diabetes Complications (EDC)
Study cohort, CAC is related to clinical coronary arterydisease (CAD) independent of other risk factors [82].
This association, however, was stronger in men than in
women [82]. In a cohort of patients with type 1 diabetes
(aged 22–50 years), progression of CAC, as identified
by electron beam computed tomography (EBCT), was
strongly associated with suboptimal glycemic control
(HbA1c >7.5%) [83].
In a study assessing CAC with multislice spiral computed
tomography (MSCT), nearly one third of asymptomatic
long-term type 1 diabetic patients presented with coronary
calcifications [84]. In patients with coronary calcifications,
both cardiac autonomic neuropathy and retinopathy
were detected more frequently than in those without
(64% vs. 29%, p < 0.02; 59% vs. 31%; p < 0.02). Additionally,
duration of diabetes was longer in patients with than with-
out coronary calcification [84].
In a small cohort of adolescent, non-obese type 1 diabetic
patients, an increased carotid intima-media thickness was
found to be associated with insulin resistance. A causal
relationship, however, cannot be concluded [85]. According
to a prospective longitudinal study in children and adoles-
cents with type 1 diabetes, systolic blood pressure and body
mass index are related to carotid intima-media thickness
increment. Control of these risk factors is supposed to
contribute to prevention of carotid intima-media thick-
ness progression [86].
In patients with long-term duration type 1 diabetes, sex-
ual dysfunction was demonstrated to be independently as-
sociated with CVD and to potentially predict CVD [87].
Results on the predictive value of plasminogen activator
inhibitor-1 (PAI-1) are inconsistent. One study found
PAI-1 levels to be independently related to CAC in
younger (< 45 years) patients with type 1 diabetes [88].
According to another analysis, neither PAI-1 nor tPA-
PAI-1 is an independent predictor of CAD [89].
Diagnosis / Screening
In type 1 diabetes, hypertension is often the result of
nephropathy. Blood pressure measurement at every
routine visit is recommended [90]. In most adult pa-
tients with diabetes, a fasting lipid profile at least once
a year is recommended [90]. Low-risk lipid values
(LDL cholesterol < 100 mg/dL, HDL > 50 mg/dL, tri-
glycerides < 150 mg/dL) provided, assessment may be
repeated biannually [90].
In type 1 diabetic patients with diabetes duration ≥ 5
years, the screening for nephropathy should include an
annual assessment of urine albumin excretion [90]. Ir-
respective of the degree of urine albumin excretion, in
all adults with diabetes serum creatinine should be
measured at least annually [90]. The creatinine value is
useful for estimation of glomerular filtration rate (GFR)
[90]. In children and adolescent patients, annual screening
both for nephropathy and retinopathy is recommended to
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and at age 9 years with 5 years duration, respectively [91].
Screening for signs and symptoms of CV autonomic
neuropathy should be started 5 years after the diagnosis
of type 1 diabetes [16,90]. CV reflex tests are the gold
standard in clinical autonomic testing. The most widely
used tests assessing cardiac parasympathetic function
are based on the time-domain heart rate response to
deep breathing, Valsalva maneuver, and postural change.
Age is a strong modulator of these tests and needs to be
considered when interpreting the results. CV sympathetic
function is assessed by measuring the blood pressure
response to standing [92].
PWA may contribute to assessment of CV risk in pa-
tients with type 1 diabetes [78]. In a study, greater aug-
mentation pressure was independently associated with
prevalent CAD and estimated myocardial perfusion
with low ABI (<0.90) [78]. Screening patients for silent
myocardial ischemia is controversial but seems reasonable
in very high risk patients, in particular in those with long
duration of diabetes and proteinuria or evidence of per-
ipheral artery disease, and in those who wish to start a vig-
orous exercise program. Measurement of CAC score may
be suggested as a first line investigation, leading to a stress
test if the score is higher than 400 [93,94].
Treatment
Gycemic control
Intensive insulin therapy has been strongly demonstrated
to reduce the onset as well as progression of all diabetes-
related microvascular complications [58,60,95-98]. The
Diabetes Control and Complications Trial (DCCT)/
Epidemiology of Diabetes Interventions and Complications
(EDIC) study found in approximately 1,200 patients with
type 1 diabetes a relative CVD risk reduction of 40%, ad-
justed for other risk factors including albuminuria, when
comparing intensive vs. standard treatment (mean HbA1c
7.4% vs. 9.1%) for 11 years [58]. In adolescent patients,
intensive treatment (HbA1c 8.1%) as compared to conven-
tional treatment (HbA1c 9.8%) has been shown to reduce
the risk and progression of background retinopathy by
53%, clinical neuropathy by 60%, and microalbuminuria by
54% [60]. A prolonged effect of early intensive approaches
was also seen in a four year follow-up of intensively treated
adolescent type 1 diabetic patients [99].
Several studies confirmed the association between poor
glycemic control and an increasing risk for nephropa-
thy [100-102], retinopathy [95,103,104], and neuropathy
[105-109]. A large proportion of patients, however, fails to
achieve glycemic targets [110-112].
GLP-1 based treatment as an add-on to insulin
Due to their action on insulin secretion and glucose
regulation, glucagone-like peptide (GLP)-1 based treatmentapproaches have been established in the treatment of type 2
diabetes. Based on in vitro and animal studies, GLP-1 based
drugs have been assumed to additionally may be effective
in preserving and even expanding the beta cell mass [113].
In a small study on 15 patients with newly detected type
1 diabetes, the addition of exenatide at onset of diabetes
has been shown to decrease insulin requirement [113].
Three groups of patients have been formed: group1
(insulin alone), group 2 (insulin and exenatide), and
group 3 (insulin and sitagliptin).
After one year, a decrease in insulin requirement of
16.7 ± 12.5, 39.8 ± 17.2, 21.2 ± 9.6 units in groups 1, 2
and 3 respectively (P = 0.0431) was detected. A mean
stimulated c peptide secretion of 0.34 ± 0.12, 0.45 ± 0.34,
0.44 ± 0.5 ng/mL was found (P = 0.8656). The maximum
percentage preservation in c peptide was observed in the
patients of group 2 [113]. Of relevance is the evidence
that GLP-1 can protect type 1 diabetic patients by both
acute hyperglycemia or hypoglycaemia induced endothe-
lial dysfunction, oxidative stress and inflammation [114].
Approaches beyond glycemic control
In contrast to DCCT/EDIC, some trials did not confirm
the association between glycemic control and CVD risk
[115-117]. Discrepancies are suggested to be based on
differences between the study populations [118]. With
view on prevention and treatment of CAD, it is recom-
mended to focus not only on glycemic control [118].
Traditional risk factors such as albuminuria, the meta-
bolic syndrome, and inflammatory markers should also
be addressed [118].
International guidelines recommend lowering blood
pressure in diabetes to prevent macro- and micro-vascular
outcomes. However, most evidence from randomized
clinical trials refers to type 2 diabetes. A goal of blood
pressure <130 and <80 mmHg has been recommended
[90,119]. The most recent recommendations of the
American Diabetes Association (ADA) set a blood pressure
goal of <140/ <80 mmHg for persons with diabetes and
hypertension; lower targets (such as <130 mm Hg) may be
appropriate in patients if the specific target can be achieved
without an additional burden of treatment [90].
Pharmacological therapy in people with diabetes and
hypertension should be with a regimen that includes either
an angiotensin converting enzyme (ACE)-inhibitor or
an angiotensin-receptor blocker (ARB) [90]. Generally,
two or more drugs are required to achieve blood pressure
targets in diabetics. Preferred combinations are either
ACE-inhibitors or ARBs (not together) with a calcium-
channel blocker or a diuretic. For the latter, both thiazide
[90] and, more recently, thiazide-like diuretics [120] are
recommended.
However, more recent appraisal of the evidence indi-
cates lack of evidence to support systolic blood pressure
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pressure between 80 and 85 mmHg [72].
In studies among patients with diabetes, regular physical
activity has been demonstrated to reduce CVD-related
and total mortality [11]. Early treatment of hypertension
has been reported to prevent end-stage kidney disease in
patients with type 1 diabetes [121]. Angiotensin-converting
enzyme (ACE) inhibitors have been demonstrated to be
effective and safe in in reducing microalbuminuria [122]. In
adolescent patients with persistent microalbuminuria,
the use of ACE inhibitors [91,100,123] or angiotensin II
receptor blockers [91] is recommended to prevent the
progression to macroalbuminuria. Furthermore, in order
to reduce progression of microalbuminuria, cessation of
smoking is strongly recommended [117,124,125].
Lifestyle modification is recommended for the improve-
ment of lipid profile. In diabetic patients with overt CVD,
statins should be added irrespective of lipid levels [90].
Statin therapy is also recommended in diabetic patients
without CVD aged > 40 years and ≥ 1 other CVD risk
factor (family history of CVD, hypertension, smoking,
dyslipidemia, albuminuria) [90]. In patients with lower CV
risk, statin therapy should be considered if LDL cholesterol
remains above 100 mg/dL [90]. In diabetic patients without
overt CVD, the goal for LDL cholesterol is 100 mg/dL
(2.6 mmol/L). In patients with overt CVD, a LDL choles-
terol goal of 70 mg/dL (1.8 mmol/L), using a high dose of a
statin, may be considered [90].
Discussion / Outlook
Despite of a remarkable improvement in life expectancy,
type 1 diabetic patients are confronted with an increased
risk of CV mortality, an evidence often underrecognized.
Further improvement may base on consequent risk assess-
ment and management of risk factors. Estimation of CV risk
including the role of surrogate markers deserves more at-
tention in the future. Currently, optimized glycemic control
is considered to be the most promising approach. Recent
research on a small group of patients suggests the addition
of exenatide at onset of diabetes to decrease insulin require-
ment. These results, however, need to be confirmed by fur-
ther investigation on larger groups of patients.
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